Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR-T Cell Therapy Trial
ChiCTR-OIN-16007723Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anti-CD19 CAR-T cells in B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma (FL) and 7 more (2 arms), sponsored by Tongji Hospital. Primary endpoints: Overall survival and Progression-free survival. Started Jan 2016; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on ChiCTR-OIN-16007723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-16007723.